Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.
about
Developmental exposure to estrogen alters differentiation and epigenetic programming in a human fetal prostate xenograft modelCCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosisRole of YY1 in the pathogenesis of prostate cancer and correlation with bioinformatic data sets of gene expressionImmunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell responseZbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.Oncogenic protein MTBP interacts with MYC to promote tumorigenesisGenetic association analysis of the RTK/ERK pathway with aggressive prostate cancer highlights the potential role of CCND2 in disease progressionYes-Associated Protein Expression Is Correlated to the Differentiation of Prostate Adenocarcinoma.The role of the transcription factor SIM2 in prostate cancer.Decreased expression of EFS is correlated with the advanced prostate cancer.Dysregulated methylation at imprinted genes in prostate tumor tissue detected by methylation microarray.Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomyMeta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients.Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.Research Resource: Androgen Receptor Activity Is Regulated Through the Mobilization of Cell Surface Receptor Networks.ksRepo: a generalized platform for computational drug repositioningThe enzymatic activity of apoptosis-inducing factor supports energy metabolism benefiting the growth and invasiveness of advanced prostate cancer cells.miR-539 inhibits prostate cancer progression by directly targeting SPAG5Caspase-1 is a novel target of p63 in tumor suppression.RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis.Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer.Dual tumor suppressing and promoting function of Notch1 signaling in human prostate cancer.Systematic analysis of the achaete-scute complex-like gene signature in clinical cancer patients.The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration.Expression and Role of PAICS, a De Novo Purine Biosynthetic Gene in Prostate Cancer.Glutamine Transporters Are Targets of Multiple Oncogenic Signaling Pathways in Prostate Cancer.Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcomeMAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer.Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer.The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.INPP4B suppresses prostate cancer cell invasionPreclinical Development of a Nontoxic Oral Formulation of Monoethanolamine, a Lipid Precursor, for Prostate Cancer Treatment.A novel approach to identify driver genes involved in androgen-independent prostate cancer.Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch.The twist box domain is required for Twist1-induced prostate cancer metastasis.
P2860
Q21131794-2A036D7D-72EB-4339-9FE3-7B55DE3CE9D2Q24311817-746548E3-BDA4-490C-B4A3-C095AD2A012FQ28541425-A3CB3A85-3AA3-47A6-9086-6CD9518902F4Q30838103-C6ABD003-93A0-40F8-86C5-BFC83BDAABEFQ31155155-4CED2C66-5730-4CF4-92FE-52E8A9E4AAF7Q33677421-D857ACE3-5684-44EC-B951-EAD1A2A93C85Q33838577-B21ECA89-0E88-462C-8150-6D5713BE5819Q33866927-7E15171A-52B7-4446-A9A7-4EEC236F27CAQ33925616-142EC88F-F84E-4B71-AC88-846E67E9C96BQ34103422-A5173640-4778-4C3A-9E14-C616FC48DA47Q34442484-A90A51A7-B6B3-4769-9080-0A05428CFD25Q34869462-D7845FD5-8638-42C3-A44E-A07D69AF04CBQ35070161-9390FDA7-15B1-4513-B094-9536DF09FC73Q35683329-3753F7AD-E1E2-40E7-B68B-CFDBD3EA12A3Q35849866-EF3378FF-1B51-4BC6-814A-C3B0F748477FQ35897569-8A7CBE54-8F87-490D-A268-CD862F880689Q35918546-5E5CEA03-19FC-443A-B89B-CB4A1516107EQ36481896-7F7C0807-6E77-4873-837C-4F6C1BE4529FQ36758507-360B5647-E3F8-46E5-8CB4-C1DD836A17FDQ36907168-4182481E-2DF9-45D2-8994-B95D99CA9055Q37149065-97ABC5FD-E812-4B7A-8984-5DA228EFF1DFQ37246050-90638559-1F7E-4753-8E69-7B2D8ABF7C56Q37266000-043EDAD8-28B2-45A0-AEC0-E342787323F5Q37394695-13BEDC04-C248-4BBE-8DE6-AE86BB19174EQ37565364-078E6A03-D500-47C8-8A36-F36004CFC30EQ37593943-132634E0-469A-4932-A4E6-7AB5D0D6521AQ38259961-669862DD-2483-4081-945E-40843BE39118Q38681961-26033FEB-D72F-45D2-8E40-4FE8F89CAD65Q38750703-4D6D8428-D644-47AC-93DB-FA1B711BEC1AQ38784791-A37EE816-FE20-426E-9D05-A837597C8D23Q38824007-2C48B149-2588-4749-AC75-7D68EBA98432Q38839830-8C2436DF-6367-4C3F-AC65-93E339FBCCC6Q38840506-B2655F40-1C3E-4556-ADB6-BE1C940C5432Q38860787-FA4CB432-5A1D-410A-A112-1A7A2B54AEEAQ38938642-0395C3A9-4C53-44A4-88A5-286E65E3A740Q38953956-DA2BA781-2144-4A92-876A-8382AF57FBDFQ38975512-CE56DF2C-C1A9-4826-BE2E-AFC5824C47B0Q38989441-B923A3D5-2141-4491-B6D6-A4A49C7C602DQ39067480-52C32354-034D-433A-9E2C-0BC6FDF2623CQ39104231-73A9646A-409C-469C-A0B7-D5F1EF60137F
P2860
Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Identification of the transcri ...... apy target in prostate cancer.
@en
type
label
Identification of the transcri ...... apy target in prostate cancer.
@en
prefLabel
Identification of the transcri ...... apy target in prostate cancer.
@en
P2093
P2860
P50
P1476
Identification of the transcri ...... apy target in prostate cancer.
@en
P2093
Glenn J Bubley
Juan-Miguel Mosquera
Martin G Sanda
Miriam Eljanne
Mohamed S Arredouani
P2860
P304
P356
10.1158/1078-0432.CCR-09-0911
P407
P577
2009-09-08T00:00:00Z